Company news

Plus Therapeutics, Inc. news in 2024

Plus Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

December 2, 2024

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

November 21, 2024

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

November 20, 2024

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

November 5, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

September 30, 2024

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 13, 2024

Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference

August 12, 2024

Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference

August 11, 2024

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

June 6, 2024

Plus Therapeutics Announces Private Placement Financing of up to $18 Million

May 5, 2024

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

April 21, 2024

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

March 24, 2024

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

March 10, 2024

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

March 4, 2024

Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024

February 26, 2024

Calls in 2024

Decks in 2024